Expression of KL-6 in patients with rheumatoid arthritis-associated interstitial lung disease
-
摘要:
目的 肺泡Ⅱ型细胞表面抗原-6(KL-6)主要表达于Ⅱ型肺泡上皮及支气管上皮细胞, 在肺部感染、间质性肺疾病中表达升高，本研究拟探讨KL-6在类风湿关节炎相关性间质性肺疾病中的表达。 方法 收集2018年1月—2020年12月在宁夏医科大学总医院风湿免疫科住院的初次诊断且未经治疗的类风湿关节炎(RA)患者68例，其中经胸部CT证实未合并肺间质病变的单纯RA患者35例，合并肺间质病变的RA(RA-ILD)患者33例，同时期健康体检者30名，分别留取3组研究对象血清及部分单纯RA组和RA-ILD组患者关节腔积液，采用EILSA法检测KL-6的表达水平。分析单纯RA组和RA-ILD组患者性别、年龄及病程等临床特征；分析单纯RA组中合并慢性阻塞性肺疾病(COPD)和未合并COPD患者血清KL-6的表达水平。 结果 单纯RA组和RA-ILD组患者性别、年龄差异无统计学意义，RA-ILD组患者病程明显长于单纯RA组[(163.50±88.07)月vs. (94.42±50.14)月，P＜0.05]；单纯RA组中，有6例患者合并COPD，与同组未合并COPD患者比较，血清KL-6水平差异无统计学意义；RA-ILD组患者血清KL-6表达水平[(100.96±14.29)U/mL]明显高于单纯RA组患者[(30.33±5.30)U/mL]及正常对照组[(26.67±2.78)U/mL]，单纯RA组血清KL-6水平与正常对照组差异无统计学意义。单纯RA患者关节腔积液KL-6水平明显低于RA-ILD患者，差异有统计学意义(P＜0.05)。 结论 KL-6在RA-ILD患者中表达增高，是反映RA-ILD患者肺间质病变严重程度的有效指标。 -
关键词:
- 肺泡Ⅱ型细胞表面抗原-6 /
- 类风湿关节炎 /
- 肺间质病变
Abstract:Objective Krebs von den Lungen-6 (KL-6) is mainly expressed in type Ⅱ alveolar epithelium and bronchial epithelial cells, and increased in lung infection, interstitial lung disease. This study plans to investigate the expression of KL-6 in rheumatoid arthritis-related interstitial lung diseases. Methods Sixty-eight patients with rheumatoid arthritis (RA) who were diagnosed for the first time and treated in the General Hospital of Ningxia Medical University from January 2018 to December 2020 were collected, including 35 patients with RA without pulmonary interstitial lesions confirmed by chest CT (RA group) and 33 patients with RA with interstitial lung disease (RA-ILD group). Another 30 healthy people at the same time were enrolled. Serum of three groups of patients and joint effusion of some patients in RA group and RA-ILD group were collected respectively, and the expression level of KL-6 was detected by ELISA. The clinical characteristics such as gender, age and course of disease of patients in RA group and RA-ILD group were analyzed. The expression level of KL-6 in serum of patients with chronic obstructive pulmonary disease (COPD) and without COPD in RA group was analyzed. Results There was no significant difference in gender and age between RA group and RA-ILD group. The course of disease in the RA-ILD group was significantly longer than that in the RA group [(163.50±88.07) months vs. (94.42±50.14) months, P < 0.05]. In RA group, there were 6 patients with COPD, and there was no significant difference in serum KL-6 level compared with patients without COPD in the same group. The expression level of serum KL-6 in RA-ILD group was (100.96±14.29) U/mL, which were significantly higher than that in RA group [(30.33±5.30) U/mL] and normal control group [(26.67±2.78) U/mL], but there was no significant difference between RA group and normal control group. The level of KL-6 in joint cavity effusion of RA patients was significantly lower than that of RA-ILD patients (P < 0.05). Conclusion The expression of KL-6 is increased in RA-ILD patients, and KL-6 is an effective index to reflect the severity of pulmonary interstitial lesions in RA-ILD patients. -
Key words:
- Krebs von den Lungen-6 /
- Rheumatoid arthritis /
- Interstitial lung disease
-
表 1 2组RA患者一般资料比较
Table 1. Comparison of general data of RA patients in 2 groups
组别 例数 性别[例(%)] 年龄
(x±s，岁)病程
(x±s，月)男性 女性 单纯RA组 35 19 16 58.33±16.54 94.42±50.14 RA-ILD组 33 13 20 61.57±11.57 163.50±88.07 统计量 0.786a 3.473b 2.953b P值 0.087 0.163 < 0.001 注：a为χ2值，b为t值。 
下载: 导出CSV
表 2 单纯RA组中合并COPD和未合并COPD患者血清KL-6水平比较(x±s，U/mL)
Table 2. Comparison of serum KL-6 levels in patients with COPD and without COPD in RA group alone (x±s, U/mL)
组别 例数 KL-6 合并COPD 6 32.06±3.72 未合并COPD 29 29.24±5.35 t值 1.013 P值 0.155
下载: 导出CSV
表 3 3组研究对象血清KL-6水平比较(x±s，U/mL)
Table 3. Comparison of serum KL-6 levels in 3 groups (x±s, U/mL)
组别 例数 KL-6 单纯RA组 35 30.33±5.30 RA-ILD组 33 100.96±14.29a 正常对照组 30 26.67±2.78b F值 85.734 P值 ＜0.001 注：与单纯RA组比较，aP＜0.001，bP=0.182。
下载: 导出CSV
表 4 2组RA患者关节腔积液KL-6水平比较(x±s，U/mL)
Table 4. Comparison of KL-6 levels in joint effusion of RA patients in 2 groups (x±s, U/mL)
组别 例数 KL-6 单纯RA组 17 7.20±1.03 RA-ILD组 19 9.81±1.79 t值 2.822 P值 0.022
下载: 导出CSV
-
[1] ZAMORA-LEGOFF J A, KRAUSE M L, CROWSON C S, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis[J]. Rheumatology (Oxford), 2017, 56(3): 344-350. [2] RAIMUNDO K, SOLOMON J J, OLSON A L, et al. Rheumatoid arthritis-interstitial lung disease in the united states: prevalence, incidence, and healthcare costs and mortality[J]. J Rheumatol, 2019, 46(4): 360-369. doi: 10.3899/jrheum.171315 [3] ZHANG H Y, CHEN L Z, WU L L, et al. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(16): e19493. DOI: 10.1097/MD.0000000000019493. [4] LEE J S, LEE E Y, HA Y J, et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease[J]. Arthritis Res Ther, 2019, 21(1): 58. doi: 10.1186/s13075-019-1835-9 [5] 朱茂治, 祝禾辰, 陈传国, 等. KL-6粘糖蛋白在百草枯中毒致肺纤维化大鼠中的表达及意义[J]. 中华全科医学, 2017, 15(11): 1835-1838, 1999. doi: 10.16766/j.cnki.issn.1674-4152.2017.11.004ZHU M Z, ZHU H C, CHEN C G, et al. Expression and significance of KL-6 mucin in paraquat-induced murine pulmonary fibrosismodel[J]. Chinese Journal of General Practice, 2017, 15(11): 1835-1838, 1999. doi: 10.16766/j.cnki.issn.1674-4152.2017.11.004 [6] 吴丽娜, 高弋, 李沃松, 等. KL-6在非小细胞肺癌术后辅助治疗性肺损伤中的诊断价值[J]. 协和医学杂志, 2021, 12(4): 496-502. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202104010.htmWU L N, GAO Y, LI W S, et al. Application value of serum kreb von den lungen-6 in the adjuvant treatment of lung injury after non-small cell lung cancer surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 496-502. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202104010.htm [7] FRIX A N, SCHONEVELD L, LADANG A, et al. Could KL-6 levels in COVID-19 help to predict lung disease[J]. Respir Res, 2020, 21(1): 309. doi: 10.1186/s12931-020-01560-4 [8] 刘倩, 赵振军, 张晓. 血清KL-6检测在结缔组织病肺间质病变中的意义[J]. 中华风湿病学杂志, 2016, 20(6): 396-399. doi: 10.3760/cma.j.issn.1007-7480.2016.06.009LIU Q, ZHAO Z J, ZHANG X. A serological biomarker in connective tissue disease-associated interstitial lung disease: Krebs von den lungen-6[J]. Chinese Journal of Rheumatology, 2016, 20(6): 396-399. doi: 10.3760/cma.j.issn.1007-7480.2016.06.009 [9] 刘鸣, 朱芸, 王明超, 等. 血清涎液化糖链抗原评估结缔组织病相关肺间质病变病情的临床价值[J]. 浙江医学, 2018, 40(22): 2477-2479. doi: 10.12056/j.issn.1006-2785.2018.40.22.2018-1649LIU M, ZHU Y, WANG M C, et al. Clinical value of serum sialoliquified glycochain antigen in the assessment of connective tissue disease-associated lung interstitial disease[J]. Zhejiang Medical Journal, 2018, 40(22): 2477-2479. doi: 10.12056/j.issn.1006-2785.2018.40.22.2018-1649 [10] ZHENG P Y, LIU X Q, HUANG H M, et al. Diagnostic value of KL-6 in idiopathic interstitial pneumonia[J]. J Thorac Dis, 2018, 10(8): 4724-4732. doi: 10.21037/jtd.2018.07.54 [11] PENG D H, LUO Y, HUANG L J, et al. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019[J]. Clin Chim Acta, 2021, 517(6): 48-53. [12] TAN I J, BARLOW J L. Sympathetic joint effusion in an urban hospital[J]. ACR Open Rheumatol, 2019, 1(1): 37-42. doi: 10.1002/acr2.1005 [13] HUANG T H, KUO C W, CHEN C W, et al. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study[J]. BMC Pulm Med, 2021, 21(1): 165. doi: 10.1186/s12890-021-01530-6 [14] JIANG Y, LUO Q, HAN Q, et al. Sequential changes of serum KL-6 predict the progression of interstitial lung disease[J]. J Thorac Dis, 2018, 10(8): 4705-4714. doi: 10.21037/jtd.2018.07.76 [15] WANG J X, ZHENG P Y, HUANG Z F, et al. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features[J]. BMC Pulm Med, 2020, 20(1): 315. doi: 10.1186/s12890-020-01336-y -
点击查看大图
表(4)
计量
- 文章访问数: 244
- HTML全文浏览量: 49
- PDF下载量: 10
- 被引次数: 0
